Condition
Geographic Atrophy (GA)
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT06541704Phase 3Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT07230834Phase 1RecruitingPrimary
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
NCT06659445Phase 2RecruitingPrimary
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Showing all 3 trials